12/26
07:24 am
rare
Gene Therapy Market Analysis,Growth, Insights and Future Outlook | Exactitude Consultancy [Yahoo! Finance]
Low
Report
Gene Therapy Market Analysis,Growth, Insights and Future Outlook | Exactitude Consultancy [Yahoo! Finance]
12/24
08:14 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $95.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $95.00 price target on the stock.
12/20
04:30 pm
rare
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/20
08:43 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Wells Fargo & Company from $75.00 to $88.00. They now have an "overweight" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Wells Fargo & Company from $75.00 to $88.00. They now have an "overweight" rating on the stock.
12/20
03:05 am
rare
NHS England Rolls Out Evkeeza® ?(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH) [Yahoo! Finance]
Medium
Report
NHS England Rolls Out Evkeeza® ?(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH) [Yahoo! Finance]
12/19
04:17 pm
rare
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome [Yahoo! Finance]
Medium
Report
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome [Yahoo! Finance]
12/19
04:05 pm
rare
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
Low
Report
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
12/19
08:07 am
rare
Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA) [Yahoo! Finance]
Low
Report
Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA) [Yahoo! Finance]
12/19
08:00 am
rare
Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
Low
Report
Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
12/5
12:49 pm
rare
Ultragenyx (RARE) Down 6.8% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
Low
Report
Ultragenyx (RARE) Down 6.8% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
12/4
08:44 am
rare
Tumor-Induced Osteomalacia Market Size to Grow USD 153 Million by 2034, With a CAGR of 2.6%| Polaris Market Research [Yahoo! Finance]
Low
Report
Tumor-Induced Osteomalacia Market Size to Grow USD 153 Million by 2034, With a CAGR of 2.6%| Polaris Market Research [Yahoo! Finance]
11/26
04:31 pm
rare
Ultragenyx to Participate in Investor Conferences in December [Yahoo! Finance]
Low
Report
Ultragenyx to Participate in Investor Conferences in December [Yahoo! Finance]
11/26
04:30 pm
rare
Ultragenyx to Participate in Investor Conferences in December
Medium
Report
Ultragenyx to Participate in Investor Conferences in December
11/21
10:21 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at JPMorgan Chase & Co. from $105.00 to $102.00. They now have an "overweight" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at JPMorgan Chase & Co. from $105.00 to $102.00. They now have an "overweight" rating on the stock.
11/20
04:30 pm
rare
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/12
11:33 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $121.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $121.00 price target on the stock.
11/9
10:30 am
rare
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
Low
Report
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
11/6
01:10 pm
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Canaccord Genuity Group Inc. from $109.00 to $121.00. They now have a "buy" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Canaccord Genuity Group Inc. from $109.00 to $121.00. They now have a "buy" rating on the stock.
11/6
12:23 pm
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
11/6
11:24 am
rare
Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates [Yahoo! Finance]
Low
Report
Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates [Yahoo! Finance]
11/6
09:30 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
Medium
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
11/6
08:07 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at HC Wainwright from $82.00 to $95.00. They now have a "buy" rating on the stock.
Medium
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at HC Wainwright from $82.00 to $95.00. They now have a "buy" rating on the stock.
11/6
02:46 am
rare
Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust Revenue Growth ... [Yahoo! Finance]
Low
Report
Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust Revenue Growth ... [Yahoo! Finance]
11/5
08:14 pm
rare
Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics [Yahoo! Finance]
Low
Report
Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics [Yahoo! Finance]
11/5
07:12 pm
rare
Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]